Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784897 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
A Phase 2 study, sponsored by Innovation Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT04784897: Completed Phase 2 study, sponsored by Innovation Pharmaceuticals.
NCT04784897 is a Phase 2 study that has completed, run by Innovation Pharmaceuticals. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04784897, a Phase 2 study, has completed, sponsored by Innovation Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The study assessed the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants
Primary Outcome
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the clinical status ordinal scale with response sustained through Day 29: 6\. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than for per protocol dosing or assessments, as appropriate); 7. Not hospitalized, limitation on activities and/or requiring home oxygen; 8. Not hospitalized, no limitations on activities
Interventions
- DRUG Placebo
- DRUG Brilacidin
- DRUG Standard of Care (SoC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-02-22 |
| Est. Completion | 2021-07-30 |
| Phase | Phase 2 |
What the finished NCT04784897 record still lists
NCT04784897 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04784897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04784897 about?
NCT04784897 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19". The study assessed the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants
What is the current status of trial NCT04784897?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2021-02-22. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT04784897?
The interventions under investigation include: Placebo (DRUG), Brilacidin (DRUG), Standard of Care (SoC) (DRUG).
Who is sponsoring clinical trial NCT04784897?
This trial is sponsored by Innovation Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04784897's enrollment target sits among peer trials
120 569th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI